Kazia Therapeutics Ltd announced it raised $2 Million in an initial filing from an offering of $2 Million

Company

Location

About

Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. The company's lead program is paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3.